Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC
May 29th 2025Panelists discuss how real-world data from a recent Mayo Clinic study confirms the promising efficacy and favorable safety profile of nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting high cystectomy-free and overall survival rates, with longer follow-up needed to assess response durability.
An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC
May 29th 2025Panelists discuss how nogapendekin alfa, an intravesical immunotherapy that stimulates a localized immune response, combined with BCG therapy, provides a novel dual approach for treating BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), targeting both local and systemic immune responses.
An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC
May 22nd 2025Panelists discuss how pembrolizumab, a PD-1 inhibitor, offers a systemic immunotherapy option for high-risk, BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) by enhancing the immune system’s ability to target cancer cells, with intravenous administration and careful monitoring for immune-related adverse effects.
FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC
May 22nd 2025Panelists discuss how recently FDA-approved therapies, including nadofaragene firadenovec, gemcitabine, and docetaxel, offer alternative treatment options for BCG-unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC), each with distinct mechanisms and administration methods.
Closing Thoughts on Urology Practice Management and Treatment of Advanced Prostate Cancer
August 25th 2023Closing out their discussion on how treatment and management of advanced prostate cancer affects their clinical practice, expert urologists consider how the therapeutic landscape continues to evolve and look toward future evolutions in care.
Scheduling and Administering Leuprolide: Key Challenges and Practical Solutions
August 18th 2023Key opinion leaders briefly review the key challenges in scheduling leuprolide administration for patients with advanced prostate cancer, including treatment delays, disease breakthrough, and insurance reimbursement, and share solutions to overcome these challenges.